Security
Verastem, Inc. Common Stock · VSTM
VSTMNASDAQCommon stockCurrentCIK 1526119Updated Oct 4, 2026
VSTM price & chart
Loading TradingView…
NASDAQ:VSTM on TradingView ↗About the company
Verastem Oncology (Nasdaq: VSTM) is a biopharmaceutical company committed to developing and commercializing new medicines to improve the lives of patients diagnosed with RAS/MAPK pathway-driven cancers. Verastem markets AVMAPKI® FAKZYNJA® CO-PACK in the U.S. Our pipeline is focused on novel small molecule drugs that inhibit critical signaling pathways in cancer that promote cancer cell survival and tumor growth, including RAF/MEK inhibition, FAK inhibition, and KRAS G12D inhibition. For more information, please visit www.verastem.com and follow us on LinkedIn.
In the news
Recent filings
SCHEDULE 13G/A - filed by ARMISTICE CAPITAL, LLC regarding Verastem, Inc.
Entry into a Material Definitive Agreement · Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement · Regulation FD Disclosure
Items 1.01, 2.03, 7.01, 9.01
Results of Operations and Financial Condition
Items 2.02, 9.01
10-Q filing
SCHEDULE 13G - filed by VANGUARD CAPITAL MANAGEMENT LLC regarding Verastem, Inc.
Show 5 more recent filings
4 filing
Regulation FD Disclosure · Other Events
Items 7.01, 8.01, 9.01
144 filing
Regulation FD Disclosure · Other Events
Items 7.01, 8.01, 9.01
S-8 filing
Financials
FY 2025 · USDSource
Source
Source
Source
Source
balance sheet · annual statements
| Line item | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|
| ASSETS | ||||
| AssetsUSD | 246,442,000Source | 101,538,000Source | 149,718,000Source | 95,050,000Source |
| Property, Plant and EquipmentUSD | — | 32,000Source | 37,000Source | 92,000Source |
| Current assets: | ||||
| Cash and Cash Equivalents, at Carrying ValueUSD | 204,990,000Source | 88,818,000Source | 77,909,000Source | 74,933,000Source |
| Accounts Receivable | — | — | — | — |
| Inventory, NetUSD | 1,833,000Source | — | — | — |
| Assets, CurrentUSD | 223,413,000Source | 94,961,000Source | 143,682,000Source | 92,870,000Source |
| Prepaid Expense and Other Assets, CurrentUSD | 7,577,000Source | 5,943,000Source | 6,553,000Source | 4,945,000Source |
| Operating Lease, Right-of-Use AssetUSD | 491,000Source | 1,405,000Source | 1,171,000Source | 1,789,000Source |
| Other Assets, NoncurrentUSD | 6,112,000Source | 4,899,000Source | 4,587,000Source | 58,000Source |
| LIABILITIES AND EQUITY | ||||
| LiabilitiesUSD | 189,245,000Source | 130,431,000Source | 71,185,000Source | 47,659,000Source |
| Stockholders’ equity: | ||||
| Common Stock, Value, IssuedUSD | 8,000Source | 4,000Source | 3,000Source | 20,000Source |
| Retained Earnings (Accumulated Deficit)USD | -1,164,998,000Source | -955,527,000Source | -824,890,000Source | -737,523,000Source |
| Accumulated Other Comprehensive Income (Loss), Net of TaxUSD | 5,229,000Source | — | 13,000Source | — |
| Stockholders' Equity Attributable to ParentUSD | 57,197,000Source | -28,893,000Source | 57,374,000Source | 47,391,000Source |
| Additional Paid in Capital, Common StockUSD | 1,216,958,000Source | 926,630,000Source | 882,248,000Source | 784,894,000Source |
| Liabilities and EquityUSD | 246,442,000Source | 101,538,000Source | 149,718,000Source | 95,050,000Source |
| Current liabilities: | ||||
| Liabilities, CurrentUSD | 72,268,000Source | 30,973,000Source | 26,380,000Source | 21,663,000Source |
| Operating Lease, Liability, CurrentUSD | 535,000Source | 995,000Source | 941,000Source | 794,000Source |
| Accounts Payable, CurrentUSD | 12,448,000Source | 4,026,000Source | 7,184,000Source | 4,901,000Source |
| Operating Lease, Liability, NoncurrentUSD | — | 535,000Source | 530,000Source | 1,470,000Source |
| Additional Financial Items | ||||
| Accrued Liabilities, CurrentUSD | 53,981,000Source | 25,952,000Source | 17,928,000Source | 14,983,000Source |
| Cash, Cash Equivalents, and Short-term InvestmentsUSD | 205,000,000Source | 88,800,000Source | — | 87,900,000Source |
| Long-term DebtUSD | — | 40,724,000Source | 40,086,000Source | 24,526,000Source |
cash flow · annual statements
| Line item | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|
| Cash flows from operating activities: | ||||
| Net Income (Loss), Including Portion Attributable to Noncontrolling InterestUSD | -209,471,000Source | -130,637,000Source | -87,367,000Source | -73,812,000Source |
| Adjustments to reconcile net income to net cash provided by operating activities: | ||||
| Share-based Payment Arrangement, Noncash ExpenseUSD | 9,404,000Source | 7,342,000Source | 5,860,000Source | 6,047,000Source |
| Changes in operating assets and liabilities: | ||||
| Increase (Decrease) in Accounts ReceivableUSD | 8,813,000Source | — | -31,000Source | -485,000Source |
| Increase (Decrease) in InventoriesUSD | 1,833,000Source | — | — | — |
| Increase (Decrease) in Accounts PayableUSD | 8,422,000Source | -3,158,000Source | 2,283,000Source | 2,599,000Source |
| Deferred Income Tax Expense (Benefit)USD | — | — | — | 0Source |
| Net Cash Provided by (Used in) Operating ActivitiesUSD | -137,509,000Source | -104,771,000Source | -86,460,000Source | -63,673,000Source |
| Cash flows from investing activities: | ||||
| Net Cash Provided by (Used in) Investing ActivitiesUSD | -9,624,000Source | 59,972,000Source | -44,447,000Source | 66,185,000Source |
| Payments to Acquire Property, Plant, and EquipmentUSD | — | 28,000Source | — | — |
| Cash flows from financing activities: | ||||
| Net Cash Provided by (Used in) Financing ActivitiesUSD | 263,305,000Source | 54,782,000Source | 134,194,000Source | 51,784,000Source |
| Repayments of Long-term DebtUSD | 42,579,000Source | — | 300,000Source | — |
| Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate EffectUSD | 116,172,000Source | 9,983,000Source | 3,287,000Source | 54,296,000Source |
| Cash, Cash Equivalents, Restricted Cash and Restricted Cash EquivalentsUSD | 205,231,000Source | 89,059,000Source | 79,076,000Source | 75,789,000Source |
| Supplemental disclosure of cash flow information: | ||||
| Interest Paid, Excluding Capitalized Interest, Operating ActivitiesUSD | 6,364,000Source | 3,774,000Source | 3,361,000Source | 1,536,000Source |
| Income Taxes Paid, NetUSD | 185,000Source | — | — | — |
| Additional Financial Items | ||||
| Share-based Payment Arrangement, ExpenseUSD | 9,405,000Source | 7,342,000Source | 5,860,000Source | 6,047,000Source |
| Amortization of Debt Issuance CostsUSD | 11,000Source | 277,000Source | 230,000Source | — |
| Amortization of Debt Issuance Costs and DiscountsUSD | 29,000Source | -5,000Source | -1,132,000Source | 228,000Source |
| Amortization of Intangible AssetsUSD | 698,000Source | — | — | — |
| Cash, Cash Equivalents, and Short-term InvestmentsUSD | 205,000,000Source | 88,800,000Source | — | 87,900,000Source |
| Debt Securities, Available-for-sale, Realized Gain (Loss)USD | 0Source | 0Source | 0Source | 0Source |
| DepreciationUSD | 30,000Source | 26,000Source | 62,000Source | 118,000Source |
| Gain (Loss) on Extinguishment of DebtUSD | -1,826,000Source | — | — | — |
| Income Tax Expense (Benefit)USD | — | 185,000Source | — | 0Source |
| Investment Income, InterestUSD | 4,068,000Source | 4,149,000Source | 6,214,000Source | 1,215,000Source |
| Net Income (Loss) Attributable to ParentUSD | -209,471,000Source | -130,637,000Source | -87,367,000Source | -73,812,000Source |
| Other Nonoperating Income (Expense)USD | -203,000Source | -123,000Source | -109,000Source | 47,000Source |
| Proceeds from Issuance of Common StockUSD | 196,976,000Source | 14,221,000Source | 91,420,000Source | 27,354,000Source |
| Proceeds from Maturities, Prepayments and Calls of Debt Securities, Available-for-saleUSD | — | 60,000,000Source | 52,000,000Source | 84,000,000Source |
| Proceeds from Stock Options ExercisedUSD | 116,000Source | 241,000Source | 57,000Source | 282,000Source |
| Restructuring CostsUSD | — | — | — | 0Source |
income statement · annual statements
| Line item | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|
| Total RevenueUSD | — | 10,000,000Source | — | 2,596,000Source |
| Selling, General and Administrative ExpenseUSD | 81,146,000Source | 43,622,000Source | 30,728,000Source | 24,975,000Source |
| Operating Income (Loss)USD | -170,129,000Source | -114,956,000Source | -92,084,000Source | -72,937,000Source |
| Other Nonoperating Income (Expense)USD | -203,000Source | -123,000Source | -109,000Source | 47,000Source |
| Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling InterestUSD | -209,471,000Source | -130,452,000Source | — | -73,812,000Source |
| Income Tax Expense (Benefit)USD | — | 185,000Source | — | 0Source |
| Net Income (Loss) Attributable to ParentUSD | -209,471,000Source | -130,637,000Source | -87,367,000Source | -73,812,000Source |
| Earnings Per Share, BasicUSD per share | -3.02Source | -3.66Source | -3.96Source | -0.38Source |
| Earnings Per Share, DilutedUSD per share | -3.02Source | -3.66Source | -3.93Source | -0.38Source |
| Weighted Average Number of Shares Outstanding, Basicshares | 69,309,000Source | 35,713,000Source | 22,054,000Source | 193,654,000Source |
| Weighted Average Number of Shares Outstanding, Dilutedshares | 69,309,000Source | 35,713,000Source | 22,054,000Source | 193,654Source |
| Additional Financial Items | ||||
| Amortization of Intangible AssetsUSD | 698,000Source | — | — | — |
| Costs and ExpensesUSD | 201,043,000Source | 124,956,000Source | 92,084,000Source | 75,533,000Source |
| Current Income Tax Expense (Benefit)USD | — | 185,000Source | — | 0Source |
| Interest ExpenseUSD | 1,138,000Source | 4,562,000Source | 4,139,000Source | 2,137,000Source |
| Investment Income, InterestUSD | 4,068,000Source | 4,149,000Source | 6,214,000Source | 1,215,000Source |
| Research and Development ExpenseUSD | 114,599,000Source | 81,334,000Source | 61,356,000Source | 50,558,000Source |
| Restructuring CostsUSD | — | — | — | 0Source |
Filing attachments
tm2622452d1_ex99-1.htm · 8-K · 2026-08-07
EX-99.1 3 tm2622452d1_ex99-1.htm EXHIBIT 99.1 Exhibit 99.1 Delivering Novel Therapies for RAS/MAPK Pathway-Driven Cancers C O R P O R A T E P R E S E N T A T I O N A U G U S T 2 0 2 6 2 FORWARD-LOOKING STATEMENTS This presentation includes forward-looking statements about, among other things, Verastem Oncology’s (the “Company”) programs and product candidates, strategy, future plans and prospects, including statements related to the approval and commercialization of AVMAP…
Read attachment ↗tm2622452d2_ex99-1.htm · 8-K · 2026-08-06
EX-99.1 2 tm2622452d2_ex99-1.htm EXHIBIT 99.1 Exhibit 99.1 Verastem Oncology Reports Second Quarter 2026 Financial Results and Highlights Recent Business Updates AVMAPKI® FAKZYNJA® CO-PACK net product revenue of $25.1 million First patients dosed in all three TARGET-D Phase 2 registration-directed clinical trials evaluating VS-7375 across 2L PDAC, 2L/3L NSCLC, and 2L+ CRC Updated clinical data for VS-7375 across pancreatic, lung, and colorectal cancers expected in October Entered into a…
Read attachment ↗vstm-20260630xex99d1.htm · 10-Q · 2026-08-06
Exhibit 99.1 Verastem Oncology Reports Second Quarter 2026 Financial Results and Highlights Recent Business Updates AVMAPKI® FAKZYNJA® CO-PACK net product revenue of $25.1 million First patients dosed in all three TARGET-D Phase 2 registration-directed clinical trials evaluating VS-7375 across 2L PDAC, 2L/3L NSCLC, and 2L+ CRC Updated clinical data for VS-7375 across pancreatic, lung, and colorectal cancers expected in October Entered into a non-dilutive royalty financing agreement with Obe…
Read attachment ↗tm2618546d1_ex99-1.htm · 8-K · 2026-06-23
EX-99.1 2 tm2618546d1_ex99-1.htm EXHIBIT 99.1 Exhibit 99.1 VS - 7375 : Potential Best - in - Class KRAS G12D (ON/OFF) Inhibitor R&D Update Call June 23, 2026 2 FORWARD - LOOKING STATEMENTS This presentation includes forward - looking statements about, among other things, Verastem Oncology’s (the “Company”) programs an d product candidates, strategy, future plans and prospects, including statements related to the approval and commercialization of AVMAPKI® FAKZYNJA® CO - PACK ( avutometinib …
Read attachment ↗tm2618108d1_ex99-1.htm · 8-K · 2026-06-17
EX-99.1 2 tm2618108d1_ex99-1.htm EXHIBIT 99.1 Exhibit 99.1 Verastem Oncology Announces Positive Updated Results from RAMP 205 Evaluating Avutometinib Plus Defactinib in Combination with Standard-of-Care Chemotherapy in First-Line Metastatic Pancreatic Cancer 90% of patients in the study presented with metastatic (Stage IV) disease at diagnosis 6-month overall survival rate was 86%; follow-up continues and survival data continue to mature BOSTON--(BUSINESS WIRE) - June 17, 2026--Verastem …
Read attachment ↗tm2613842d1_ex99-1.htm · 8-K · 2026-05-07
EX-99.1 2 tm2613842d1_ex99-1.htm EXHIBIT 99.1 Exhibit 99.1 Delivering Novel Therapies for RAS/MAPK Pathway-Driven Cancers C O R P O R A T E P R E S E N T A T I O N M A Y 2 0 2 6 2 FORWARD-LOOKING STATEMENTS This presentation includes forward-looking statements about, among other things, Verastem Oncology’s (the “Company”) programs and product candidates, strategy, future plans and prospects, including statements related to the approval and commercialization of AVMAPKI® FAKZ…
Read attachment ↗